Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Locally Advanced Pancreatic Cancer
Interventions
DRUG

Nimotuzumab+ NALIRIFOX

"Drug: Nimotuzumab Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600mg, 600mg, 400mg on Day 1, 8, 15, respectively, 28 days as a cycle, up to 6 cycles.~Other Names: h-R3~Drug: NALIRIFOX Patients will receive NALIRIFOX (liposomal irinotecan 50 mg/m2, oxaliplatin 60 mg/m2, leucovorin 400 mg/m2, and fluorouracil 2400 mg/m2, administered sequentially as a continuous intravenous infusion over 46 h) on days 1 and 15 of a 28-day cycle, up to 6 cycles.~Other Names: NALIRIFOX"

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06429904 - Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer | Biotech Hunter | Biotech Hunter